School of Life Sciences, Northeast Normal University, Changchun, PR China.
Pharm Biol. 2011 Mar;49(3):283-9. doi: 10.3109/13880209.2010.511235.
Novel antimalarial agents are in demand due to the emergence of multidrug resistant strains. Ginseng, a medicinal plant with antiparasitic activity, contains components that can be used to treat the tropical disease malaria.
Ginsenosides and polysaccharides are active components of ginseng. This study aimed to elucidate the ability of these compounds to inhibit the replication of Plasmodium yoelii in an attempt to determine whether the medicinal uses of ginseng are supported by pharmacological effects. New antimalarial compounds may be developed from ginsenosides and water-soluble ginseng polysaccharides (WGP).
Ginsenosides and ginseng polysaccharides were prepared from ginseng. Antimalarial activities were examined by 4-day tests and repository tests. Macrophage phagocytosis was tested in normal and malaria-bearing mice.
Ginseng polysaccharides could inhibit residual malaria infection. After a 6-day treatment, the parasitemia reductions of WGP and acidic ginseng polysaccharide (WGPA) were 55.66% and 64.73% at 200 mg/kg/day, respectively. Ginsenosides showed significant antimalarial activity on early infection. Protopanaxadiol-type ginsenosides caused 70.97% chemosuppression at 50 mg/kg/day, higher than 52.8% of total ginsenosides at the same dose.
Protopanaxadiol-type ginsenosides have remarkably suppressive activity during early infection, while acidic ginseng polysaccharides have significant prophylactic activity against malaria by stimulating the immune system. We propose that the activity of ginsenosides is dependent upon non-specific carbohydrate interactions and that the activity of ginseng polysaccharides is due to immunological modulation. Ginsenosides and ginseng polysaccharides might have a potential application in antimalarial treatments.
由于出现了多药耐药株,新型抗疟药物的需求不断增加。人参是一种具有抗寄生虫活性的药用植物,其成分可用于治疗热带疾病疟疾。
人参皂苷和多糖是人参的活性成分。本研究旨在阐明这些化合物抑制疟原虫(Plasmodium yoelii)复制的能力,以确定人参的药用价值是否得到药理作用的支持。新型抗疟化合物可能来源于人参皂苷和水溶性人参多糖(WGP)。
从人参中提取人参皂苷和人参多糖。通过 4 天试验和贮存试验检测抗疟活性。在正常和疟原虫感染的小鼠中检测巨噬细胞吞噬作用。
人参多糖可抑制残留疟原虫感染。经 6 天治疗,WGP 和酸性人参多糖(WGPA)在 200mg/kg/天时的疟原虫减少率分别为 55.66%和 64.73%。人参皂苷对早期感染显示出显著的抗疟活性。在 50mg/kg/天时,原人参二醇型人参皂苷的化学抑制率为 70.97%,高于相同剂量下总人参皂苷的 52.8%。
原人参二醇型人参皂苷在早期感染时具有显著的抑制活性,而酸性人参多糖通过刺激免疫系统对疟疾具有显著的预防作用。我们提出,人参皂苷的活性依赖于非特异性碳水化合物相互作用,而人参多糖的活性则归因于免疫调节。人参皂苷和人参多糖可能具有抗疟治疗的应用潜力。